Headquartered in Chinachem Leighton Plaza, Causeway Bay Fiscal year ends June NASDAQ: RGC regencellbioscience.com
Regencell Bioscience Holdings Limited is an early-stage bioscience company focused on the research, development, and commercialization of Traditional Chinese Medicine (TCM) for the treatment of neurocognitive disorders, specifically Attention Deficit Hyperactivity Disorder (ADHD) and Autism Spectrum Disorder (ASD). The company operates through wholly owned subsidiaries in Hong Kong and the British Virgin Islands. Regencell holds exclusive intellectual property rights to TCM formulas developed under a strategic partnership agreement with its TCM Practitioner. The company is pre-revenue and has not generated any revenue since its inception in 2014. It trades on the Nasdaq Capital Market under the symbol 'RGC'. The company is currently subject to a U.S. Department of Justice investigation into trading activity in its ordinary shares, as well as a putative class action lawsuit. Management has expressed substantial doubt about the company's ability to continue as a going concern. Updated
Finding top growth stocks with the kind of capital appreciation upside long-term investors are seeking is the name of the game for a solid majority of investors in the market right now.…
The top analyst upgrades, downgrades and other research calls from Tuesday include Abbott Labs, Delphi, Lululemon, Netflix, Nordstrom, Sirius XM, Disney and Windstream.
The top analyst upgrades, downgrades and other research calls from Thursday include Barrick Gold, Buffalo Wild Wings, Caterpillar, Coca-Cola, GrubHub, Nabors Industries and Wynn Resorts.
The top analyst upgrades, downgrades and other research calls from Wednesday include AMD, Apple, Biogen, Capital One, Chipotle Mexican Grill, General Motors and 3M.
The top analyst upgrades, downgrades and other research calls from Thursday include CarMax, DowDuPont, Gilead Sciences, GrubHub, Microsoft, Nike and Western Digital.
If Credit Suisse is right, movie theater chains feel like they are at death's door in the summer of 2017.
Will movie studios, theater owners, and streaming services be able to reach an agreement that shortens the time between a movie's release and its availability to stream on-demand?
Credit Suisse cut its ratings for a few of the largest movie theaters chains, after forecasting weaker domestic attendance growth despite a strong movie slate for 2017.
The top analyst upgrades, downgrades and initiations seen on Monday morning include Cypress Semiconductor, Groupon, Humana, Infosys, Monster Beverage and Transocean.
A new JPMorgan study suggests that the reduction in average gas prices in the United States has not resulted in an increase in savings.
The top analyst upgrades, downgrades and initiations seen on Monday morning include Advanced Micro Devices, Agios Pharmaceuticals, Baidu, Diamond Offshore Drilling, LyondellBasell and Occidental Petroleum.
Tuesday's top analyst calls include Encana, Fortinet, Halliburton, Red Hat, Sanmina, Stratasys and Vodafone.
Thursday's top analyst upgrades, downgrades and initiations include AT&T, Capstone Turbine, ConAgra Foods, Diamond Offshore Drilling and Hecla Mining.
Wednesday's top analyst upgrades and downgrades include Apple, Annaly Capital, Jabil Circuit, Lululemon, Xerox and WebMD.
ThinkstockThe initial public offering (IPO) for AMC Entertainment Holdings Inc. (NYSE: AMC) priced 18.4 million shares at the low end of its expected range of $18 to $20 after markets closed Tuesday…
Regencell Bioscience Holdings Limited is an early-stage bioscience company focused on the research, development, and commercialization of Traditional Chinese Medicine (TCM) for the treatment of neurocognitive disorders, specifically Attention Deficit Hyperactivity Disorder (ADHD) and Autism Spectrum Disorder (ASD).
